Multiplex Tumor Marker Panel for Gynecologic Cancers (Multianalyte Tissue-Specific Biomarker Profile)

What This Test Measures

The test evaluates a combination of proteins and other substances (biomarkers) that are often elevated in patients with gynecologic cancers. These biomarkers may come from tumor cells or the body’s response to cancer. The specific markers included could include but are not limited to substances like CA-125, CEA, or other tumor-associated proteins, depending on the panel configuration. The test may also include tissue-specific markers that reflect the type of cancer or its activity level.

Why It Might Be Ordered

Your healthcare provider may order this test if you have symptoms suggestive of gynecologic cancer (e.g., abnormal vaginal bleeding, persistent pelvic pain), if you have a known history of gynecologic cancer, or as part of a screening or monitoring plan for early detection or treatment follow-up.

Sample Collection and Preparation

A blood sample is typically drawn from a vein in your arm. The blood is processed to separate the serum or plasma, which contains the biomarkers being tested. This sample is then sent to a laboratory for analysis using advanced techniques such as immunoassays or mass spectrometry to detect the presence and levels of specific biomarkers.

Common Uses in Diagnosis and Monitoring

This test can assist in diagnosing suspected gynecologic cancers by providing additional information about the presence of cancer cells or their activity. It may also be used to monitor treatment effectiveness, detect recurrence, or assess the progression of disease over time. Results are often interpreted alongside clinical findings, imaging studies, and other diagnostic tests.